Exchange & Returns Information
Review Details
(0)
| Generic For | HYDREA |
|---|---|
| Active Ingredient | HYDROXYUREA |
| Strength | 500MG |
| Manufacturer | SAMARTH LIFE SCIENCES |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 100 CAPSULES | $ 0.40 | $ 39.90 |
$ 33.92
Apply ZARVY26 (-15%)
You save $ 5.99
|
||
| 2 BOXES - 200 CAPSULES | $ 0.41 | $ 81.90 |
$ 69.62
Apply ZARVY26 (-15%)
You save $ 12.29
|
||
| ★ Best Value 3 BOXES - 300 CAPSULES | $ 0.41 | $ 121.90 |
$ 103.62
Apply ZARVY26 (-15%)
You save $ 18.29
|
Reference information will be available soon.
Durea 500 is an oral capsule formulation containing 500mg of hydroxyurea, a well-established antimetabolite chemotherapeutic agent. It works by inhibiting ribonucleotide reductase, an essential enzyme for DNA synthesis. By disrupting DNA replication, hydroxyurea exerts cytotoxic effects primarily on rapidly dividing cells, making it effective in hematologic malignancies such as chronic myeloid leukemia (CML), polycythemia vera, and essential thrombocythemia.
Additionally, hydroxyurea has shown disease-modifying effects in sickle cell disease by enhancing fetal hemoglobin (HbF) levels, which improves red blood cell flexibility and reduces hemolysis. Its oral route, affordability, and extensive clinical use make it a cornerstone drug in both oncology and hematology.
AntiCancer Drugs > Chronic Myeloid Leukemia (CML)
Used as a cytoreductive agent in patients with elevated white blood cell counts at diagnosis or disease progression. It helps reduce leukocyte burden before initiating targeted therapies such as tyrosine kinase inhibitors. It is also employed in combination with radiotherapy or chemotherapy in select resistant cases.
AntiCancer Drugs > Polycythemia Vera & Essential Thrombocythemia
Hydroxyurea is the first-line therapy for high-risk patients with excessive red blood cell or platelet production. It prevents thrombotic complications such as stroke and deep vein thrombosis by regulating hematologic parameters. Treatment is long-term and personalized based on tolerance and response.
DISEASES/SYMPTOMS > Sickle Cell Anemia
Approved for both adult and pediatric patients to reduce vaso-occlusive crises and the need for blood transfusions. Hydroxyurea increases fetal hemoglobin (HbF), which reduces red cell sickling and improves overall disease outcomes. It also lowers hospitalization rates and improves quality of life.
Hydroxyurea acts by selectively inhibiting ribonucleotide reductase, an enzyme crucial for deoxyribonucleotide production. This leads to cell cycle arrest in the S phase, particularly affecting rapidly dividing myeloid cells.
In CML, it reduces leukocytosis, mitigating splenomegaly and thrombosis risk.
In sickle cell disease, hydroxyurea increases HbF through mechanisms involving erythropoiesis stimulation and nitric oxide pathways. Elevated HbF interferes with polymerization of sickled hemoglobin, reducing pain crises and acute chest syndrome.
The dual action as a cytoreductive and hemoglobin-modifying agent makes hydroxyurea uniquely versatile across hematologic indications.
Chronic Myelogenous Leukemia (CML)
→ Dosage: Individualized; start with standard oral capsule
→ Adjust based on WBC count and tolerance
→ Monitor CBC weekly during titration
→ Ensure correction of anemia before initiation
→ Supplement with folic acid
Use: Cytoreduction in CML patients with high WBC or resistance to standard therapy
Head and Neck Cancer
→ Used with radiation or chemoradiation protocols
→ Dose tailored to patient weight and tumor type
→ Requires close blood count monitoring
→ Folic acid co-administration advised
Use: Adjunct therapy for locally advanced squamous cell carcinoma (excluding lip)
Sickle Cell Anemia – Adults
→ Start: 15 mg/kg orally once daily
→ Increase by 5 mg/kg/day every 12 weeks
→ Max: 35 mg/kg/day
→ Dose adjustments based on CBC thresholds
→ Monitor every 2 weeks during titration
→ Folic acid strongly recommended
Use: Reduces vaso-occlusive events and transfusion frequency in recurrent sickle cell disease
Sickle Cell Anemia – Pediatrics
→ Start: 20 mg/kg once daily
→ Increase by 5 mg/kg/day every 8 weeks
→ Max: 35 mg/kg/day
→ Monitor CBC every 2 weeks
→ Tablet form may be split for accurate pediatric dosing
→ Folic acid supplementation required
Use: Approved for children ≥2 years to reduce sickling complications and improve hemoglobin parameters
Administration Tips
→ Take at the same time daily, with or without food
→ Swallow capsules whole; do not crush or chew
→ Maintain hydration to support renal elimination
→ Wear gloves when handling capsules due to cytotoxicity
→ Store in a dry place away from heat and light
Store below 25°C in a cool, dry environment
Keep in original container and away from direct sunlight
Do not freeze
Keep out of reach of children
Handle with care to avoid contact with capsule contents
Common: Bone marrow suppression (neutropenia, anemia), nausea, loss of appetite
Less Common: Hair thinning, pigmentation changes, skin ulceration
Rare: Secondary leukemia with long-term use, hepatic or renal dysfunction
Monitoring: Regular CBCs and liver/renal panels are required
Management: Discontinue or adjust dosage if significant cytopenia develops
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
